Pitcairn Co. Has $2.54 Million Position in Zoetis Inc. $ZTS

Pitcairn Co. cut its holdings in Zoetis Inc. (NYSE:ZTS) by 42.9% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 17,346 shares of the company’s stock after selling 13,049 shares during the period. Pitcairn Co.’s holdings in Zoetis were worth $2,538,000 as of its most recent filing with the SEC.

Several other hedge funds have also recently added to or reduced their stakes in ZTS. Brighton Jones LLC lifted its holdings in shares of Zoetis by 180.4% during the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company’s stock worth $754,000 after buying an additional 2,978 shares during the last quarter. Empowered Funds LLC increased its position in Zoetis by 6.2% during the first quarter. Empowered Funds LLC now owns 11,293 shares of the company’s stock worth $1,859,000 after acquiring an additional 657 shares during the period. Intech Investment Management LLC raised its stake in Zoetis by 17.2% during the 1st quarter. Intech Investment Management LLC now owns 8,347 shares of the company’s stock valued at $1,374,000 after purchasing an additional 1,224 shares during the last quarter. Sivia Capital Partners LLC raised its stake in Zoetis by 73.8% during the 2nd quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company’s stock valued at $522,000 after purchasing an additional 1,422 shares during the last quarter. Finally, Sigma Planning Corp boosted its holdings in Zoetis by 3.1% in the 2nd quarter. Sigma Planning Corp now owns 3,325 shares of the company’s stock valued at $518,000 after purchasing an additional 100 shares during the period. Institutional investors own 92.80% of the company’s stock.

Analyst Upgrades and Downgrades

ZTS has been the topic of several research reports. BTIG Research restated a “buy” rating and set a $160.00 price objective on shares of Zoetis in a report on Thursday, February 26th. HSBC set a $140.00 target price on Zoetis in a research report on Wednesday, December 10th. Piper Sandler reaffirmed a “neutral” rating and issued a $135.00 price target (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. Wall Street Zen upgraded Zoetis from a “hold” rating to a “buy” rating in a research report on Saturday, February 21st. Finally, Stifel Nicolaus lowered their price objective on Zoetis from $140.00 to $130.00 and set a “hold” rating on the stock in a research report on Tuesday, November 18th. Six research analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $152.91.

Zoetis Stock Down 3.1%

Shares of ZTS opened at $122.06 on Friday. The company has a quick ratio of 1.94, a current ratio of 3.03 and a debt-to-equity ratio of 2.71. The company has a 50-day moving average price of $126.16 and a two-hundred day moving average price of $133.42. The stock has a market cap of $51.53 billion, a price-to-earnings ratio of 20.28, a P/E/G ratio of 1.92 and a beta of 0.95. Zoetis Inc. has a 12 month low of $115.25 and a 12 month high of $177.00.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating the consensus estimate of $1.40 by $0.08. The company had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a return on equity of 62.02% and a net margin of 28.24%.The company’s revenue was up 3.0% compared to the same quarter last year. During the same period in the prior year, the company posted $1.40 EPS. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. Equities analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Zoetis Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 2nd. Shareholders of record on Monday, April 20th will be issued a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.7%. Zoetis’s dividend payout ratio (DPR) is presently 35.22%.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.